Status:

UNKNOWN

Glaser Obesity Study

Lead Sponsor:

Glaser Pediatric Research Network

Collaborating Sponsors:

Elizabeth Glaser Pediatric AIDS Foundation

Conditions:

Obesity

Eligibility:

All Genders

13-18 years

Phase:

PHASE2

PHASE3

Brief Summary

This study will determine if the drug metformin, coupled with diet and exercise counseling, will help obese adolescents lose weight.

Detailed Description

America is facing an epidemic of obesity among its youth. In the last seven years, there has been a 50% increase in the prevalence of obesity as defined by a Body Mass Index (BMI) \> 30 kg/m². For the...

Eligibility Criteria

Inclusion

  • Subjects must be between the ages of 13.00 and 17.99 at week 0 (Baseline).
  • Subjects must have a BMI ≥ 95th percentile for age and gender using the CDC data (see Appendix), but must weigh less than 300 pounds (\<136 kilograms) when measured during the initial physical exam at week 0 (Baseline). BMI will be calculated as follows; weight in kilograms  \[height in meters\]2. This cutoff has been established due to the weight-bearing limits of the table used in performing the DXA scan. Once enrolled, if a subject's weight progresses above 300 pounds, s/he may continue in the study whether it is possible to perform DXA or not.
  • Completion of informed consent/assent process

Exclusion

  • Known diabetes as defined by the American Diabetes Association criteria
  • Prior drug therapy to treat diabetes or insulin insensitivity, including any form of insulin or insulin analogs; or any oral antidiabetic medication; acarbose, acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide, metformin, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide or troglitazone.
  • Prior use of drugs to aid in weight loss, including but not limited to: Benzphetamine Hcl, Diethylpropion Hcl, Fenfluramine Hcl, Phendimetrazine Tartrate, Phentermine Hcl, Orlistat, Sibutramine Hcl Monohydrate, Didrex, Tenuate, Pondimin, Bontril-SR, Adipex-P, Fastin, Ionamin, Phentrol, Xenical, Meridia.
  • Subject is currently taking the following medications at the time of the Screening visit: Cimetidine, amiloride, digoxin, furosemide, morphine, nifedipine, procainamide, ranitidine, triamterene, trimethoprim, vancomycin and quinidine, as these medications may increase metformin levels.
  • Subjects will be excluded from the study if they have taken prescription-strength glucocorticoids (by any route) within three months of the screening visit. Topical glucocorticoids are acceptable if their strength is no greater than the equivalent of 1% hydrocortisone cream.
  • History of any syndrome or medical disorder associated with significant obesity, including but not limited to: Prader Willi Syndrome, Bardet-Biedl Syndrome, Cohen Syndrome, Cushing syndrome or disease.
  • Prior surgical therapy for obesity
  • Subject to be excluded if s/he has attended a formal weight loss program within 6 months prior to the Screening visit.
  • In the 6 months prior to Screening, subject has consumed alcohol more frequently than twice per week and/or subject has had more than three alcohol-containing beverages in a 24 hour period.
  • Elevated creatinine (\> 1.2 mg/dl)
  • Untreated disorders of thyroid function
  • Elevated liver enzymes (Alanine Aminotransferase \[ALT\] or Aspartate Aminotransferase \[AST\]) \> 80 (approximately 2 times upper limit of normal)
  • Mobility impairment that prevents full participation in recommended physical activity
  • Other serious medical condition that the Principal Investigator or Lead Site Investigator determines may put the patient at undue risk if enrolled in the study
  • Unable to comply with the protocol in the opinion of the Principal Investigator or the Lead Site Investigator
  • Subjects with child-bearing potential who are unwilling to remain abstinent or use an effective method of birth control
  • Previous pregnancy

Key Trial Info

Start Date :

October 1 2003

Trial Type :

INTERVENTIONAL

End Date :

November 1 2007

Estimated Enrollment :

76 Patients enrolled

Trial Details

Trial ID

NCT00209482

Start Date

October 1 2003

End Date

November 1 2007

Last Update

October 5 2006

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

University of California, Los Angeles

Los Angeles, California, United States, 90095

2

University of California, San Francisco

San Francisco, California, United States, 94143

3

Stanford University

Stanford, California, United States, 94305

4

Children's Hospital, Boston

Boston, Massachusetts, United States, 02115

Glaser Obesity Study | DecenTrialz